ENGN enGene Holdings Inc.
USHealthcareAs of 2026-08-24
Why ENGN matters now
enGene Holdings Inc. (ENGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.81 with +1.69% on the session and $121.3M in market capitalization; recent performance reads 1-month +12.42% and YTD -80.95%.
The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $30.2M, and EPS of $0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -126.5%.
The latest indexable market news headline is "Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)" from Defense World.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.50; recent insider activity includes Zoth Lota S. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.47
P/S
0.00
EV/EBITDA
-0.53
DCF Value
$0.28
FCF Yield
-126.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-29.3%
ROA
-21.6%
ROIC
-23.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $30.2M | $0.43 |
| Q1 2026 | $0.00 | $-29.8M | $-0.44 |
| Q4 2025 | $0.00 | $-37.9M | $-0.74 |
| FY 2025 | $0.00 | $-117.3M | $-2.29 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$6.13
Target (Median)
$3.50
Target Range
$2.00 - $28.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
-0.29
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.